New therapeutic target for metabolic syndrome: PPARδ

Endocrine Journal

Volumn 54, Issue 3, 2007, Pages 347-357

  Takahashi, Sadao ^a   Tanaka, Toshiya ^b   Sakai, Juro ^b,c  

^a UNIVERSITY OF FUKUI   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

Author keywords

Atherosclerosis; Fatty acids metabolism; Glucose metabolism; Metabolic syndrome; PPAR

Indexed keywords

2 [1 CARBOXY 2 [4 [2 (5 METHYL 2 PHENYL 4 OXAZOLYL)ETHOXY]PHENYL]ETHYLAMINO]BENZOIC ACID METHYL ESTER; 2 [4 [2 [3 (2,4 DIFLUOROPHENYL) 1 HEPTYLUREIDO]ETHYL]PHENYLTHIO] 2 METHYLPROPIONIC ACID; 4 [4 [3 (4 ACETYL 3 HYDROXY 2 PROPYLPHENOXY)PROPOXY]PHENOXY]ACETIC ACID; [2 METHYL 4 [4 METHYL 2 (4 TRIFLUOROMETHYLPHENYL) 5 THIAZOLYLMETHYLTHIO]PHENOXY]ACETIC ACID; AD 5075; GW 0742; GW 1514; GW 2090; GW 5101516; GW 610742; GW 647; GW 7647; GW 957; GW 9820; N (2 BENZOYLPHENYL) O [2 (METHYL 2 PYRIDINYLAMINO)ETHYL]TYROSINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PIRINIXIC ACID; ROSIGLITAZONE; UNCLASSIFIED DRUG; WY 1339;

ADIPOSE TISSUE; ATHEROSCLEROSIS; CARBOHYDRATE METABOLISM; CARCINOGENESIS; ENERGY EXPENDITURE; FATTY ACID OXIDATION; GENETIC POLYMORPHISM; HEART MUSCLE CELL; HUMAN; KNOCKOUT MOUSE; LIPOPROTEIN METABOLISM; METABOLIC SYNDROME X; NONHUMAN; PROTEIN ANALYSIS; REVIEW; SKELETAL MUSCLE;

ADIPOSE TISSUE; ANIMALS; ATHEROSCLEROSIS; CARBOHYDRATE METABOLISM; ENERGY METABOLISM; FATTY ACIDS; HUMANS; LIPOPROTEINS; LIVER; METABOLIC SYNDROME X; MICE; MICE, KNOCKOUT; MODELS, BIOLOGICAL; MUSCLE, SKELETAL; NEOPLASMS; OXIDATION-REDUCTION; POLYMORPHISM, SINGLE NUCLEOTIDE; PPAR DELTA;

EID: 34547136480     PISSN: 09188959     EISSN: 13484540     Source Type: Journal    
DOI: 10.1507/endocrj.KR-99     Document Type: Review

References (62)

1. Lefebvre P, Chinetti G, Fruchart JC, Staels B (2006) Sorting out the roles of PPARα in energy metabolism and vascular homeostasis. J Clin Invest 116: 571-580.
2. Semple RK, Chatterjee KK, O'Rahilly S (2006) PPARγ and human metabolic disease. J Clin Invest 116: 581-589.
3. Barish GD, Narkae VA, Evans RM (2006) PPARδ: a dagger in the heart of the metabolic syndrome. J Clin Invest 116: 590-597.
4. Leone TC, Weinheimer CJ, Kelly DP (1999) A critical role for the peroxisome proliferators activated receptor α (PPARα) in the cellular fasting response: The PPARα-null mouse as a model of fatty acid oxidation disorders. Proc Natl Acad Sci USA 96: 7473-7478.
5. Kersten S, Seydoux J, Peters JM, Gonzalez FJ, Desvergne B, Wahli W (1999) Peroxisome proliferator-activated receptor α mediates the adaptive response to fasting. J Clin Invest 103: 1489-1498.
6. Eckel RH, Grundy SM, Zimmet PZ (2005) The metabolic syndrome. Lancet 365: 1415-1428.
7. Schmidt A, Endo N, Rutledge SJ, Vogel R, Shinar D, Rodan GA (1992) Identification of a new member of the steroid hormone receptor superfamily that is activated by a peroxisome proliferator and fatty acids. Mol Endocrinol 6: 1634-1641.
8. Escher P, Braissant O, Basu-Modak S, Michalik L, Wahli W, Desvergne B (2001) Rat PPARs: quantitative analysis in adult rat tissues and regulation in fasting and refeeding. Endocrinology 142: 4195-4202.
9. Chawla A, Lee CH, Barak Y, He W, Rosenfeld J, Liao D, Han J, Kang H, Evans RM (2003) PPARδ is a very low-density lipoprotein sensor in macrophages. Proc Natl Acad Sci USA 100: 1268-1273.
10. Lee CH, Kang K, Mehl IR, Nofsinger R, Alaynick WA, Chong LW, Rosenfeld JM, Evans RM (2006) Peroxisome proliferator-activated receptor δ promotes very low-density lipoprotein-derived fatty acid catabolism in the macrophage. Proc Natl Acad Sci USA 103: 2434-2439.
11. Peters JM, Lee SST, Li W, Ward JM, Gavrilova O, Everett C, Reitman ML, Hudson LD, Gonzalez FJ (2000) Growth, adipose, brain, and skin alterations resulting from targeted disruption of the mouse peroxisome proliferator- activated receptor β (δ). Mol Cell Biol 20: 5119-5128.
12. Barak Y, Liao D, He W, Ong ES, Nelson MC, Olefsky JM, Boland R, Evans RM (2002) Effects of peroxisome proliferator-activated receptor δ on placentation, adiposity, and colorectal cancer. Proc Natl Acad Sci USA 99: 303-308.
13. Michalik L, Desvergne B, Tan NS, Basu-Modak S, Escher P, Rieusset J, Peters JM, Kaya G, Gonzalez FJ, Zakany J, Metzger D, Chambon P, Duboule D, Wahli W (2001) Impaierd skin wound healing in peroxisome proliferator-activated receptor (PPAR) α and PPARβ mutant mice. J Cell Biol 154: 799-814.
14. Nadra K, Anghel SI, Joye E, Tan NS, Basu-Modak S, Treno D, Wahli W, Desvergne B (2006) Differentiation of trophoblast giant cells and their metabolic functions are dependent on peroxisome proliferator-activated receptor β (δ). Mol Cell Biol 26: 3266-3281.
15. Bastie C, Holst D, Gaillard D, Jehl-Pietri C, Grimaldi PA (1999) Expression of peroxisome proliferator-activated receptor PPARδ promotes induction of PPARγ and adipocyte differentiation in 3T3C2 fibroblast. J Biol Chem 274: 21920-21925.
16. Bastie C, Luquet S, Holst D, Jehl-Pietri C, Grimaldi PA (2000) Alterations of peroxisome proliferator-activated receptor δ activity affect fatty acid-controlled adipose differentiation. J Biol Chem 275: 38768-38773.
17. Hansen JB, Zhang H, Rasmussen TH, Petersen RK, Flindt EN, Kristiansen K (2001) Peroxisome proliferator-activated receptor δ (PPARδ)-mediated regulation of preadipocyte proliferation and gene expression is dependent on cAMP signaling. J Biol Chem 276: 3175-3182.
18. Wang YX, Lee CH, Tiep S, Yu RT, Ham J, Kang H, Evans RM (2003) Peroxisome proliferator-activated receptor δ activates fat metabolism to prevent obesity. Cell 113: 159-170.
19. Oram JF, Heinecke JW (2005) ATP-binding cassette transporter A1: a cell cholesterol exporter that protects against cardiovascular disease. Physiol Rev 85: 1343-1372.
20. Leibowitz MD, Fiévet C, Hennuyer N, Peinado-Onsurb J, Duez H, Berger J, Cullinan CA, Sparrow CP, Baffic J, Berger CD, Santini C, Marquis RW, Tolman RL, Smith RG, Moller DE, Auwerx J (2000) Activation of PPARδ alters lipid metabolism in db/db mice. FEBS Lett 473: 333-336.
21. Oliver WR Jr, Shenk JL, Snaith MR, Russell CS, Plunket KD, Bodkin NL, Lewis MC, Winegar DA, Sznaidman ML, Lambert MH, Xu HE, Sternbach DD, Kliewer SA, Hansen BC, Willson TM (2001) A selective peroxisome proliferator-activated receptor δ promotes reverse cholesterol transport. Proc Natl Acad Sci USA 98: 5306-5311.
22. Van der Veen JN, Kruit JK, Havinga R, Baller JFW, CHimini G, Lestavel S, Staels B, Groot PHE, Groen AK, Kuipers F (2006) Reduced cholesterol absorption upon PPARδ activation coincides with decreased intestinal expression of NPC1L1. J Lipid Res 46: 526-534.
23. Akiyama TE, Lambert G, Nicol CJ, Matsusue K, Peters JM, Brewer HB Jr, Gonzalez FJ (2004) Peroxisome proliferator-activated receptor β/δ regulates very low density lipoprotein production and catabolism in mice on a western diet. J Biol Chem 279: 20874-20881.
24. Vosper H, Patel L, Graham TL, Khoudoli GA, Hill A, Macphee CH, Pinto I, Smith SA, Suckling KE, Wolf CR, Palmer CAN (2001) The peroxisome proliferator-activated receptor δ promotes lipid accumulation in human macrophages. J Biol Chem 276: 44258-44265.
25. Zhang J, Fu M, Zhu X, Xiao Y, Mou Y, Zheng H, Akinbami MA, Wang Q, Chen YE (2002) Peroxisome proliferator-activated receptor δ is up-regulated during vascular lesion formation and promotes post-confluent cell proliferation in vascular smooth muscle cells. J Biol Chem 277: 11505-11512.
26. Libby P (2002) Inflammation in atherosclerosis. Nature 420: 868-874.
27. Welch JS, Ricote M, Akiyama TE, Gonzalez FJ, Glass CK (2003) PPARγ and PPARδ negatively regulate specific subsets of lipopolysaccharide and IFN-γ target genes in macrophages. Proc Natl Acad Sci USA 100: 6712-6717.
28. Lee CH, Chawla A, Urbiztondo N, Liao D, Boisvert WA, Evans RM (2003) Transcriptional repression of atherogenic inflammation: modulation by PPARδ. Science 302: 453-457.
29. Li AC, Binder CJ, Gutierrez A, Brown KK, Plotkin CR, Pattison JW, Valledor AF, Davis RA, Willson TM, Witztum JL, Palinski W, Glass CK (2004) Differential inhibition of macrophage foam-cell formation and atherosclerosis in mice by PPAR α, β/δ, γ. J Clin Invest 114: 1564-1576.
30. Graham TL, Mookherjee C, Suckling KE, Palmer CNA, Patel L (2005) The PPARδ agonist GW0742X reduces atherosclerosis in LDLR -/- mice. Atherosclerosis 181: 29-37.
31. Muoio DM, MacLean PS, Lang DB, Li S, Houmard JA, Way JM, Winegar DA, Corton JC, Dohm GL, Kraus WE (2002) Fatty acid homeostasis and induction of lipid regulatory genes in skeletal muscles of peroxisome proliferator-activated receptor (PPAR) α knockout mice. J Biol Chem 277: 26089-26097.
32. Tanaka T, Yamamoto J, Iwasaki S, Asaba H, Hamura H, Ikeda Y, Watanabe M, Magoori K, Ioka RX, Tachibana K, Watanabe Y, Uchiyama Y, Sumi K, Iguchi H, Ito S, Doi T, Hamakubo T, Naito M, Auwerx J, Yanagisawa M, Kodama T, Sakai J (2003) Activation of peroxisome proliferator-activated receptor δ induces fatty acid β-oxidation in skeletal muscle and attenuates metabolic syndrome. Proc Natl Acad Sci USA 100: 15924-15929.
33. Dressel U, Allen TL, Pippal JB, Rohde PR, Lau P, Muscat GEO (2003) The peroxisome proliferators-activated receptor β/δ agonist, GW501516, regulates the expression of genes involved in lipid catabolism and energy uncoupling in skeletal muscle cells. Mol Endocrinol 17: 2477-2493.
34. Holst D, Luquet S, Nogueira V, Kristiansen K, Leverve X, Grimaldi PA (2003) Nutritional regulation and role of peroxisome proliferator-activated receptor δ in fatty acid catabolism in skeletal muscle. Biochim Biophys Acta 1633: 43-50.
35. Luquet S, Lopez-Soriano J, Holst D, Fredenrich A, Melki J, Rassoulzadegan M, Grimaldi PA (2003) Peroxisome proliferator-activated receptor δ controls muscle development and oxidative capability. FASEB J 17: 2299-2301.
36. Wang YX, Zhang CL, Yu RT, Cho HK, Nelson MC, Bayuga-Ocampo CR, Ham J, Kang H, Evans RM (2004) Regulation of muscle fiber type and running endurance by PPARδ. PLoS Biol 2: e294.
37. Krämer DK, Al-Khalili L, Perrini S, Skogsberg J, Wretenberg P, Kannisto K, Wallberg-Henriksson H, Ehrenborg E, Zierath JR, Krook A (2005) Direct activation of glucose transport in primary human myotubes after activation of peroxisome proliferator-activated receptor δ. Diabetes 54: 1157-1163.
38. Lee CH, Olson P, Hevener A, Mehl I, Chong LW, Olefsky JM, Gonzalez FJ, Ham J, Kang H, Peters JM, Evans RM (2006) PPARdelta regulates glucose metabolism and insulin sensitivity. Proc Natl Acad Sci USA 103: 3444-3449.
39. Gilde AJ, van der Lee KAJM, Willemsen PHM, Chinetti G, van der Leij FR, van der Vusse GJ, Staels B, van Bilsen M (2003) Peroxisome proliferator- activated receptor (PPAR) α and PPARβ/δ, but not PPARγ, modulate the expression of genes involved in cardiac lipid metabolism. Circ Res 92: 518-524.
40. Cheng L, Ding G, Qin Q, Xiao Y, Woods D, Chen YE, Yang Q (2004) Peroxisome proliferators-activated receptor δ activates fatty acid oxidation in cultured neonatal and adult cardiomyocytes. Biochem Biophys Res Commun 313: 277-286.
41. Cheng L, Ding G, Qin Q, Huang Y, Lewis W, He N, Evans RM, Schneider MD, Brako FA, Xiao Y, Chen YE, Yang Q (2004) Cardiomyocyte-restricted peroxisome proliferator-activated receptor-δ deletion perturbs myocardial fatty acid oxidation and leads to cardiomyopathy. Nat Med 10: 1245-1250.
42. Petrashevskaya NN, Schwarz A (2005) Peroxisome proliferators-activated receptor β/δ: A new antihypertrophic drug target? Cardiovasc Res 65: 770-771.
43. Planavila A, Laguna JC, Vázques-Carrera M (2005) Nuclear factor-κB activation leads to down-regulation of fatty acid oxidation during cardiac hypertrophy. J Biol Chem 280: 17464-17471.
44. Planavila A, Rodríguez-Calvo R, Jové M, Michalik L, Wahli W, Laguna JC, Vázques-Carrera M (2005) Peroxisome proliferators-activated receptor δ/δ activation inhibits hypertrophy in neonatal rat cardiomyocytes. Cardiovasc Res 65: 832-841.
45. Ding G, Cheng L, Qin Q, Frontin S, Yang Q (2006) PPARδ modulates lipopolysaccharide-induced TNFα inflammation signaling in cultured cardiomyocytes. J Mol Cell Cardiol 40: 821-828.
46. Pesant M, Sueur S, Dutartre P, Tallandier M, Grimaldi PA, Rochette L, Connat JL (2006) Peroxisome proliferators-activated receptor δ (PPARδ) activation protects H9c2 cardiomyoblasts from oxidative stress-induced apoptosis. Cardiovasc Res 69: 440-449.
47. He TC, Chan TA, Vogelstein B, Kinzler KW (1999) PPARδ is an APC-regulated target of nonsteroidal anti-inflammatory drugs. Cell 99: 335-345.
48. Gupta RA, Tan J, Krause WF, Geraci MW, Willson TM, Dey SK, DuBois RN (2000) Prostacyclin-mediated activation of peroxisome proliferator-activated receptor δ in colorectal cancer. Proc Natl Acad Sci USA 97:13275-13280.
49. Shao J, Sheng H, DuBois RN (2002) Peroxisome proliferator-activated receptors modulate K-Ras-mediated transformation of intestinal epithelial cells. Cancer Res 62: 3282-3288.
50. Gupta RA, Wang D, Katkuri S, Wang H, Dey SK, DuBois RN (2004) Activation of nuclear hormone receptor peroxisome proliferator-activated receptor-δ accelerates intestinal adenoma growth. Nat Med 10: 245-247.
51. Park BH, Vogelstein B, Kinzler KW (2001) Genetic disruption of PPARδ decreases the tumorigenicity of human colon cancer cells. Proc Natl Acad Sci USA 98: 2598-2603.
52. Harman FS, Nicol CJ, Marin HE, Ward JM, Gonzalez FJ, Peters JM (2004) Peroxisome proliferator-activated receptor-δ attenuates colon carcinogenesis. Nat Med 10: 481-483.
53. Reed KR, Sansom OJ, Hayes AJ, Gescher AJ, Winton DJ, Peters JM, Clarke AR (2004) PPARdelta status and Apc-mediated tumourigenesis in the mouse intestine. Oncogene 23:8992-8996.
54. Reed KR, Sansom OJ, Hayes AJ, Gescher AJ, Peters LM, Clarke AR (2006) PPARδ status and mismatch repair mediated neoplasia in the mouse intestine. BMC Cancer 6:113.
55. Marin HE, Peraza MA, Billin AN, Willson TM, Ward JM, Kennett MJ, Gonzales FJ, Peters JM (2006) Ligand activation of peroxisome proliferator-activated receptor-β inhibits colon carcinogenesis. Cancer Res 66: 4394-4401.
56. Skogsberg J, Kannisto K, Cassel TN, Hamsten A, Eriksson P, Ehrenborg E (2003) Evidence that peroxisome proliferator-activated receptor delta influences cholesterol metabolism in men. Arterioscler Thromb Vasc Biol 23: 637-643.
57. Skogsberg J, McMahson AD, Karpe F, Hamsten A, Packard CJ, Ehrenborg E (2003) Peroxisome proliferator-activated receptor delta genotype in relation to cardiovascular risk factors and risk of coronary heart disease in hypercholesterolaemic men. J Int Med 254: 597-604.
58. Aberle J, Hopfer I, Beil FU, Seedorf U (2006) Association of the T+294C polymorphism in PPARδ with low cholesterol and coronary heart disease risk in women. Int J Med Sci 3: 108-111.
59. Gouni-Berthold I, Giannakidou E, Faust M, Berthold HK, Krone W (2005) The peroxisome proliferator-activated receptor delta +294T/C polymorphism in relation to lipoprotein metabolism in patients with diabetes mellitus type 2 and in non-diabetic controls. Atherosclerosis 183: 336-341.
60. Shin HD, Park BL, Kim LH, Jung HS, Cho YM, Moon MK, Park YJ, Lee HK, Park KS (2004) Genetic polymorphisms in peroxisome proliferator-activated receptor δ associated with obesity. Diabetes 53: 847-851.
61. Andrulionyté L, Peltola P, Chiasson JL, Laakso M (2006) Single nucleotide polymorphisms of PPARD in combination with the Gly482Ser substitution of PGC-1A and the Pro12Ala substitution of PPARG2 predict the conversion from impaired glucose tolerance to type 2 diabetes. Diabetes 55: 2148-2152.
62. Vänttinen M, Nuutila P, Kuulasmaa T, Pihlajamäki J, Hällsten K, Virtanen KA, Lautamäki R, Peltoniemi P, Takala T, Viljanen APM, Knuuti J, Laakso M (2005) Single nucleotide polymorphisms in the peroxisome proliferator-activated receptor δ gene are associated with skeletal muscle glucose uptake. Diabetes 54: 3587-3591.